Analysis of antimicrobial resistance in clinical strains of Klebsiella pneumoniae
pdf

Keywords

multidrug-resistant K. pneumonia
resistance mecha-nisms
beta-lactamases
carbapenemases
resistance genes

How to Cite

ANTON, M., MIHALACHI, N. and BURDUNIUC, O. (2023) “Analysis of antimicrobial resistance in clinical strains of Klebsiella pneumoniae”, One Health & Risk Management , p. 12. Available at: https://journal.ohrm.bba.md/index.php/journal-ohrm-bba-md/article/view/591 (Accessed: 9June2025).

Abstract

Introduction. In recent years, the resistance of Klebsiella pneumoniae species, both to reserve antimicrobials and to several groups of antimicrobial preparations (MDR), has emerged as a significant global public health concern. K. pneumoniae exhibits a variety of antimicrobial resistance mechanisms and is a common pathogen responsible for surgical wound infections, gastrointestinal tract infections, urinary tract infections, and community-acquired infections that can trigger nosocomial infection outbreaks. Numerous studies have shown that a majority of infections linked to various medical devices, including urinary and intravascular catheters, were attributed to K. pneumoniae, with approximately 90% of these strains being biofilm producers. According to a report by the CDC, of the 9,000 infections caused by carbapenem-resistant Enterobacteriaceae species documented in 2013, around 80% were attributed to K. pneumoniae. Currently, the global antimicrobial resistance rate for K. pneumoniae is estimated to be approximately 70%, with a mortality rate ranging between 40% and 70%. Aim. Determination of resistance profiles and detection of resistance mechanisms in K. pneumoniae strains isolated from clinical biosubstrates. Material and methods. For the determination of K. pneumoniae strains producing extended-spectrum beta-lactamases and/or carbapenemases, phenotypic tests (double disk synergy test, combined disk test (MastDisk Combi), Amp-C test with cloxacillin, Normand Poirel test, MAST CARBA PacE) and molecular genetic tests were performed. Through the Combo Test, Combi Carba Plus tests and the immunochromatographic method, the KPC, OXA-48, MBL (NDM, VIM, IMP) type enzymes that confer resistance to the bacteria were highlighted. Confirmation of resistance mechanisms was performed by the molecular-genetic method. Results. Between 2020 and 2022, a total of 867 (76.8%) K. pneumoniae strains were isolated and reported from urine and 262 (23.2%) strains - from blood and CSF. The resistance profiles of K. pneumoniae indicate worrying levels of resistance to all groups of antimicrobial preparations, such as: penicillins – 76.5%, fluoroquinolones – 78.4%, 3rd generation cephalosporins – 82.8%, 4th generation cephalosporins – 64, 1%, aminoglycosides – 71.6%, including carbapenems – 40.5% and colistin – 23.5%. ESBL-producing strains are increasing, from 17.5% confirmed strains in 2020 to 33.6% confirmed isolates in 2022. Among the 66.5% strains suspected of producing carbapenemases, 35.7% isolates were identified by the immunochromatographic method, including OXA-48 type presented 34.4% strains of K. pneumoniae, NDM type – 13.9%, IMP type – 4.9% strains, KPC and VIM type – 0.2% strains each. Through the multiplex PCR, 29.4% strains of K. pneumoniae with resistance genes were confirmed. In 28.8% of isolates, the blaOXA-48 gene was determined. Alarmingly, 10.0% strains showed 2 or more resistance mechanisms simultaneously. Conclusions. K. pneumonia is the most common pathogen involved in the etiology of invasive infections. The resistance levels of this species have reached alarming levels, even with reserve antimicrobials. In the investigated K. pneumoniae species, a wide array of resistance enzymes was identified, with the most frequent being OXA-48, followed by NDM.

Note: This paper has been authored as part of the project: 20.80009.8007.09 “Studying the mechanisms of antimicrobial resistance in gram-negative bacilli to enhance the national surveillance system.”

pdf

|Views: 139| |pdf Downloads: 38|


pdf
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.

ANNOUNCEMENT

Starting from July 1, 2025, the article processing fee will be 20 EUR (or the equivalent in MDL at the official exchange rate of the National Bank of Moldova). The publication fee for an accepted article will be 150 EUR (or the equivalent in MDL).

Details here:

Processing Fee
A processing fee of 20 EUR (or the equivalent in MDL) will be charged for articles accepted for scientific review by the editorial committee of the One Health and Risk Management journal.
Note: This fee will only be charged if your article has been technically reviewed and accepted.

Publication Fee
Starting from 01.07.2025, a fee of 150 EUR (or the equivalent in MDL) will be charged for articles accepted for publication.
Additionally, authors will bear the cost of English language editing/translation services if the manuscript requires intervention. The fee is 5 EUR (or the equivalent in MDL) per page edited/translated.
The total cost for English editing/translation services will be communicated by the Editorial Board after the manuscript is accepted for publication.

Payment Details:
Payments should be made in MDL to the bank account opened in the name of the Biosafety and Biosecurity Association of the Republic of Moldova.
The invoice will be issued by the end of the month in which the payment was made.

Organization: Biosafety and Biosecurity Association of the Republic of Moldova
Address: 5C A. Cozmescu Street
Fiscal Code: 1017620004120
Bank Code (SWIFT): AGRNMD2X451
IBAN: MD34AG000000022513622370